Clearside Biomedical

Clearside Biomedical EV/EBITDA

Delisted

The EV/EBITDA (Enterprise Value to EBITDA) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 0.57. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 1.02 — a change of -44.12% (lower).

EV/EBITDA

0.57

YoY

-44.12%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Clearside Biomedical is 2024 0.57 . EV/EBITDA (Enterprise Value to EBITDA) of Clearside Biomedical was 2023 1.02 . It decreases by -44.12% lower compared to the previous year.

The Clearside Biomedical EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2017
0.45 USD
Jan 1, 2018
0.33 USD
Jan 1, 2019
0.46 USD
Jan 1, 2020
0.71 USD
Jan 1, 2021
43.42 USD
Jan 1, 2022
1.48 USD
Jan 1, 2023
1.02 USD
Jan 1, 2024
0.57 USD
The Clearside Biomedical EV/EBITDA history
YEAREV/EBITDAYoY
0.57-44.12%
1.02-30.81%
1.48-96.60%
43.42+5,995.02%
0.71+54.95%
0.46+39.28%
0.33-26.16%
0.45-84.47%
2.88+362.37%
0.62+28.67%
0.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

EV/EBITDA (Enterprise Value to EBITDA) of Clearside Biomedical is 0.57 in 2024.

EV/EBITDA (Enterprise Value to EBITDA) of Clearside Biomedical changed from 1.02 to 0.57, representing a -44.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Clearside Biomedical

All Key Metrics — Clearside Biomedical